Notification of transactions by person discharging managerial responsibilities.
February 15, 2018 - Shire Plc (LSE: SHP, NASDAQ: SHPG) (the “Company”)
Notification of transactions by person discharging managerial responsibilities
| 1. | Details of the person discharging managerial responsibilities (“PDMR”) / person closely associated them (“PCA”) | ||
| a) | Name | Flemming Ornskov, MD, MPH | |
| 2. | Reason for the notification | ||
| a) | Position / status | Chief Executive Officer - PDMR | |
| b) | Initial notification / amendment | Initial notification | |
| 3. | Details of the issuer, emission allowance participant, auction platform, auctioneer or auction monitor | ||
| a) | Name | Shire plc | |
| b) | LEI | 54930005LQRLI2UXRQ59 | |
| 4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||
| a) | Description of the financial instrument, type of instrument | Shire plc American Depositary Shares (“ADSs”)
| |
| Identification code | ISIN: US82481R1068 | ||
| b) | Nature of the transaction | Release of ADSs awarded under the Shire Executive Annual Incentive on February 13, 2015. In accordance with the relevant plan rules, upon release the number of ADSs to be delivered was increased by an amount equivalent to the value of dividends paid by the Company in respect of the ADSs from the award date to the date of release. (Details of related disposals of ADSs are referenced in section 5. below.) | |
| c) | Price(s) and volume(s) | Price(s) | Volume(s) |
| $0 | 2,546 | ||
| d) | Aggregated information - Aggregated volume - Price | N/A (single transaction) | |
| e) | Date of the transaction | February 13, 2018 | |
| f) | Place of the transaction | N/A | |
| 5. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||
| a) | Description of the financial instrument, type of instrument | Shire plc American Depositary Shares (“ADSs”)
| |
| Identification code | ISIN: US82481R1068 | ||
| b) | Nature of the transaction | Automated disposal of ADSs in relation to the release of ADSs referenced in section 4. above. The proceeds of this disposal were used to satisfy personal tax liabilities arising from the release of the ADSs. | |
| c) | Price(s) and volume(s) | Price(s) | Volume(s) |
| See appendix below | |||
| d) | Aggregated information - Aggregated volume - Price | Weighted average price | Aggregate volume |
| $132.0104
| 1,572
| ||
| e) | Date of the transaction | February 13, 2018 | |
| f) | Place of the transaction | ARCX / CDRG / CROS / DBAX / EBXL / INET / NITE / NQPX | |
Appendix
| Place of the transaction | Aggregate volume | Weighted average price |
| ARCX | 369 | $132.1072 |
| CDRG | 200 | $131.9800 |
| CROS | 200 | $131.9800 |
| DBAX | 100 | $131.9900 |
| EBXL | 100 | $131.9850 |
| INET | 203 | $131.9716 |
| NITE | 300 | $131.9800 |
| NQPX | 100 | $131.9900 |
| Total | 1,572 | $132.0104 |
Oliver Strawbridge
Senior Assistant Company Secretary
For further information please contact:
| Investor Relations | ||
| Christoph Brackmann | christoph.brackmann@shire.com | +41 795 432 359 |
| Robert Coates | rcoates@shire.com | +44 203 549 0874 |
| Sun Kim | sun.kim@shire.com | +1 617 588 8175 |
| Media | ||
| Lisa Adler | lisa.adler@shire.com | +1 617 588 8607 |
| Katie Joyce | kjoyce@shire.com | +1 781 482 2779 |
NOTES TO EDITORS
About Shire
Shire is the global leader in serving patients with rare diseases. We strive to develop best-in-class therapies across a core of rare disease areas including hematology, immunology, genetic diseases, neuroscience, and internal medicine with growing therapeutic areas in ophthalmics and oncology. Our diversified capabilities enable us to reach patients in more than 100 countries who are struggling to live their lives to the fullest.
We feel a strong sense of urgency to address unmet medical needs and work tirelessly to improve people’s lives with medicines that have a meaningful impact on patients and all who support them on their journey.
